Short Interest in Aytu BioPharma, Inc. (NASDAQ:AYTU) Declines By 14.4%

Aytu BioPharma, Inc. (NASDAQ:AYTU) was the target of a significant drop in short interest during the month of October. As of October 31st, there was short interest totalling 192,800 shares, a drop of 14.4% from the October 15th total of 225,200 shares. Based on an average daily trading volume, of 24,700 shares, the short-interest ratio is currently 7.8 days. Currently, 3.2% of the shares of the company are sold short.

Institutional Investors Weigh In On Aytu BioPharma

A number of large investors have recently bought and sold shares of AYTU. Stonepine Capital Management LLC lifted its stake in Aytu BioPharma by 6.0% during the 3rd quarter. Stonepine Capital Management LLC now owns 500,958 shares of the company’s stock valued at $1,177,000 after acquiring an additional 28,489 shares during the period. Armistice Capital LLC purchased a new position in shares of Aytu BioPharma during the second quarter worth $736,000. Finally, Dimensional Fund Advisors LP raised its holdings in shares of Aytu BioPharma by 54.5% during the second quarter. Dimensional Fund Advisors LP now owns 23,551 shares of the company’s stock worth $69,000 after purchasing an additional 8,311 shares during the last quarter. Hedge funds and other institutional investors own 33.49% of the company’s stock.

Aytu BioPharma Price Performance

Shares of AYTU remained flat at $1.55 during trading hours on Friday. 63,806 shares of the stock were exchanged, compared to its average volume of 40,254. The company has a debt-to-equity ratio of 0.35, a current ratio of 0.99 and a quick ratio of 0.79. The stock has a 50-day simple moving average of $2.21 and a two-hundred day simple moving average of $2.61. Aytu BioPharma has a 12-month low of $1.49 and a 12-month high of $3.45.

Aytu BioPharma (NASDAQ:AYTU) last posted its quarterly earnings results on Thursday, September 26th. The company reported ($0.82) earnings per share for the quarter, missing the consensus estimate of ($0.45) by ($0.37). The firm had revenue of $17.98 million for the quarter. Aytu BioPharma had a negative net margin of 8.28% and a negative return on equity of 21.89%.

Aytu BioPharma Company Profile

Aytu Biopharma, Inc, a commercial-stage pharmaceutical company, focuses on commercializing novel therapeutics and consumer healthcare products the United States and internationally. The company operates through two segments: Rx segment and Consumer Health segment. The Rx segment offers prescription products for the treatment of attention deficit hyperactivity disorder (ADHD), including Adzenys XR-ODT for patients from six years and older, and Cotempla XR-ODT for patients from six to seventeen years old.